Vincent Lucente, MD
Urogynecology and Reconstructive Pelvic Surgery · Allentown, PANPI 1669414488
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Coloplast at 36.7% of the total. Reporting peaked in 2019 at $185,918 and has fallen 52.2% since, to $88,891 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 999 payments — averaging $799.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$293K
- Femselect Inc.$163K
- AbbVie$99K
- LINA Medical USA Inc$55K
- Contura, Inc.$45K
- Axonics, Inc.$34K
- plus $109K from 25 others
Across 213 payments — averaging $1479.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$186K
- Axonics, Inc.$45K
- AbbVie$38K
- Boston Scientific$14K
- Sumitomo Pharma America, Inc.$11K
- Astellas Pharma Global Development$7K
- plus $13K from 3 others
Across 8 payments — averaging $12,500 each. An ownership or investment interest held by the physician or an immediate family member.
- Femselect Inc.$50K
- Valencia Technologies Corporation$50K
What the payments were for
- Consulting fees$365,98546%
- Speaking & faculty fees$158,37420%
- Travel & lodging$94,34012%
- Food & beverage$25,9523%
- Education$153,75019%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 260 | $293,052 |
| Femselect Inc. | 87 | $162,955 |
| AbbVie(2 entities) | 175 | $99,172 |
| LINA Medical USA Inc | 16 | $55,310 |
| Contura, Inc. | 33 | $44,733 |
| Axonics, Inc. | 118 | $34,458 |
| Valencia Technologies Corporation | 19 | $30,631 |
| Medtronic(2 entities) | 65 | $24,009 |
| Escala Medical Inc. | 7 | $13,764 |
| Sumitomo Pharma America, Inc. | 33 | $10,179 |
| Astellas Pharma US Inc | 69 | $7,634 |
| Urovant Sciences Inc | 18 | $5,568 |
| Duchesnay USA Incorporated | 10 | $5,018 |
| Sunovion Pharmaceuticals Inc. | 2 | $3,850 |
| Hologic Sales And Service, LLC | 12 | $2,925 |
| Intuitive Surgical | 12 | $2,807 |
| Pfizer | 27 | $460 |
| Teleflex LLC | 3 | $394 |
| Boston Scientific | 6 | $394 |
| Carbon Medical Technologies, Inc. | 1 | $300 |
| Johnson & Johnson | 5 | $272 |
| Arthrex | 1 | $147 |
| Millicent US Inc | 4 | $99 |
| AMAG Pharmaceuticals, Inc. | 6 | $91 |
| Therapeuticsmd, Inc. | 2 | $49 |
| Baxter Healthcare | 3 | $42 |
| Bluewind Medical | 1 | $26 |
| Myovant Sciences Inc. | 1 | $22 |
| Caldera Medical, Inc | 1 | $18 |
| Mission Pharmacal Company | 1 | $17 |
| Urocure LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$274,980
- EnPlace$128,828
- BOTOX$94,966
- NEUGUIDE$88,762
- Bulkamid$50,298
- Axonics r-SNM System$30,852
- eCoin Device Kit$30,469
- GEMTESA$18,809
- ALTAVIVA$18,524
- Osphena$4,901
- Saffron$2,858
- Da Vinci Surgical System$2,520
- AXIS$2,406
- TITAN$500
- INTERSTIM$351
- Barrigel$350
- InjecSure$300
- RESTORELLE$224
- ARTHREX$147
- Axonics$131
How this compares
$798,402 in reported general payments places this provider in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.
See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 156 | $113,581 |
| PremarinEstrogens, Conjugated | 72 | $30,333 |
| GemtesaVibegron | 49 | $28,553 |
| Estradiol | 116 | $7,050 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 236 | $2,287 |
| Methenamine Hippurate | 18 | $1,112 |
| Solifenacin Succinate | 29 | $894 |
| Ciprofloxacin Hcl | 69 | $427 |
| Trospium Chloride | 13 | $421 |
| Clobetasol Propionate | 17 | $317 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 125 | $184 |
| Cephalexin | 32 | $182 |
| Fluconazole | 39 | $162 |
| Gabapentin | 17 | $18 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $7,634 | $113,581156 claims |
| PfizerPremarin | $460 | $30,33372 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $10,179 | $28,55349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.
Other urogynecology and reconstructive pelvic surgery in Allentown
- Miles MurphyAllentown$54K
- Perrin DowningAllentown$9K
- Nabila NoorAllentown$7K
- Devon SmithAllentown$1K
- Heather GottliebNewtown$48K
- Michael BonidieMechanicsburg$39K
- Lily AryaPhiladelphia$34K
- Julie DroletYork$29K
- Alexander BrusckeQuakertown$24K
- Marc TogliaMedia$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.